- Home
- RAND vs IGMS Comparison
RAND vs IGMS Comparison
Compare RAND & IGMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RAND
- IGMS
- Stock Information
- Founded
- RAND 1969
- IGMS 1993
- Country
- RAND United States
- IGMS United States
- Employees
- RAND N/A
- IGMS N/A
- Industry
- RAND Finance: Consumer Services
- IGMS Biotechnology: Pharmaceutical Preparations
- Sector
- RAND Finance
- IGMS Health Care
- Exchange
- RAND Nasdaq
- IGMS Nasdaq
- Market Cap
- RAND 80.9M
- IGMS 82.1M
- IPO Year
- RAND N/A
- IGMS 2019
- Fundamental
- Price
- RAND $18.77
- IGMS $1.17
- Analyst Decision
- RAND
- IGMS Hold
- Analyst Count
- RAND 0
- IGMS 8
- Target Price
- RAND N/A
- IGMS $6.14
- AVG Volume (30 Days)
- RAND 17.9K
- IGMS 200.2K
- Earning Date
- RAND 03-10-2025
- IGMS 03-06-2025
- Dividend Yield
- RAND 27.01%
- IGMS N/A
- EPS Growth
- RAND 35.26
- IGMS N/A
- EPS
- RAND 3.42
- IGMS N/A
- Revenue
- RAND $8,559,285.00
- IGMS $2,679,000.00
- Revenue This Year
- RAND N/A
- IGMS $134.71
- Revenue Next Year
- RAND N/A
- IGMS $74.27
- P/E Ratio
- RAND $5.60
- IGMS N/A
- Revenue Growth
- RAND 16.64
- IGMS 25.77
- 52 Week Low
- RAND $13.69
- IGMS $1.12
- 52 Week High
- RAND $31.89
- IGMS $22.50
- Technical
- Relative Strength Index (RSI)
- RAND 38.99
- IGMS 33.91
- Support Level
- RAND $18.62
- IGMS $1.17
- Resistance Level
- RAND $26.00
- IGMS $1.31
- Average True Range (ATR)
- RAND 1.40
- IGMS 0.08
- MACD
- RAND -0.18
- IGMS 0.04
- Stochastic Oscillator
- RAND 6.10
- IGMS 14.52
About RAND Rand Capital Corporation
Rand Capital Corp is a closed-end, diversified management company. The firm's investment objectives is to maximize the total return to the shareholders with current income combined with capital appreciation. Some of its portfolios include lumious, and GiveGab among others.
About IGMS IGM Biosciences Inc.
IGM Biosciences Inc is a biotechnology company engaged in the development of IgM antibody therapeutics for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. Its IgM antibody technology platform is suited for developing T cell engagers, receptor cross-linking agonists, and targeted cytokines. Its product candidate, Aplitabart: An IgM antibody targeting Death Receptor 5 (DR5) proteins, for the treatment of colorectal cancer; Imvotamab: A bispecific for severe systemic lupus erythematosus (SLE) and one for severe rheumatoid arthritis (RA); and IGM-2644: A bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins, currently planned for evaluation in autoimmune disease.